COMPARISON BETAXOLOL AND METOPROLOL TARTRATE THERAPIES IN PATIENTS WITH ARTERIAL HYPERTENSION ASSOCIATED WITH STABLE ANGINA
<p><strong>Aim.</strong> To compare antihypertensive, antianginal and antiischemic efficacy of β1-selective adrenoblockers (betaxolol and metoprolol tartrate) in patients with arterial hypertension (HT) of 1-2 degree associated with stable angina class II.</p><p><str...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | http://www.rpcardio.ru/jour/article/view/621 |
| Summary: | <p><strong>Aim.</strong> To compare antihypertensive, antianginal and antiischemic efficacy of β1-selective adrenoblockers (betaxolol and metoprolol tartrate) in patients with arterial hypertension (HT) of 1-2 degree associated with stable angina class II.</p><p><strong>Material and methods.</strong> 100 patients (aged 23-66 y.o.) with HT associated with stable angina or without angina were involved in the study. Patients were randomized into 2 groups (G1 and G2). G1 patients were treated with betaxolol, and G2 patients – with metoprolol tartrate. Ambulatory BP and electrocardiogram monitoring, exercise stress-test, echocardiography, evaluating of respiratory function, blood analysis was performed initially and in 30 and 90 days of treatment.</p><p><strong>Results.</strong> Target BP level was reached in 44 (88%) patients treated with betaxolol (average daily dose 10±4 mg). 34 patients of G1 took 10 mg daily. Target BP level was reached in 41 (82%) patients treated with metoprolol tartrate (average daily dose 150±27 mg). 30 patients of G2 took 150 mg daily. Exercise tolerance increased and a number of ischemic ST segment depressions reduced significantly in both groups. There were no significant differences in antihypertensive, antianginal, and antiischemic efficacy between groups.</p><p><strong>Conclusion.</strong> Betaxolol advantage is an ability to maintain target BP level more than 24 hours. A possibility to take betaxolol once a day raises patient’s compliance with therapy.</p> |
|---|---|
| ISSN: | 1819-6446 2225-3653 |